Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human ...

Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced positi ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new ...

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix ...

(MENAFN- Investor Brand Network) Tonix Pharmaceuticals (NASDAQ: TNXP) is working to improve organ transplant success rates with TNX-1500, a third-generation CD40L blocker designed to modulate the ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a ...

Tonix's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting ...

CHATHAM, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a ...

Kiniksa Pharmaceuticals is stopping development of a midphase autoimmune asset and returning a drug candidate to AstraZeneca as it doubles down on its cardiovascular disease pipeline. The asset ...

细胞毒性T细胞抗肿瘤免疫应答主要取决于cDC1s的交叉呈递抗原的能力。一旦激活并通过CD40-CD40L相互作用感知到辅助T细胞，cDC1就会提供关键的共刺激配体和细胞因子，以建立和维持CD8+T细胞免疫反应，这种同源T细胞活化的调节过程称为交叉启动。 在癌症小鼠模型 ...